Találati lista | Tudóstér

001-es BibID:	BIBFORM115283
035-os BibID:	(Scopus)85174198606
Első szerző:	Váradi Melinda
Cím:	Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice : results of a multicentric, retrospective study / Melinda Váradi, Orsolya Horváth, Orsolya Módos, Tamás Fazekas, Camilla M. Grunewald, Günter Niegisch, Ulrich Krafft, Viktor Grünwald, Boris Hadaschik, Csilla Olah, Anikó Maráz, Andrea Furka, Miklós Szűcs, Péter Nyirády, Tibor Szarvas
Dátum:	2023
ISSN:	2045-2322
Megjegyzések:	Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n= 210, n= 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk immune checkpoint inhibitor therapy urothelial carcinoma
Megjelenés:	Scientific Reports. - 13 (2023), p. 1-11. -
További szerzők:	Horváth Orsolya Módos Orsolya Fazekas Tamás (1950-) (kardiológus) Grunewald, Camilla M. Niegisch, Günter Krafft, Ulrich Grünwald, Viktor Hadaschik, Boris Oláh Csilla Maráz Anikó Furka Andrea (1976-) (sebész) Szűcs Miklós (urológus SOTE) Nyirády Péter Szarvas Tibor (urológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: